Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review

Title:Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review

Volume: 24 Issue: 27

Author(s): Ron Batash , Noam Asna *, Pamela Schaffer, Nicole Francis and Moshe Schaffer

Affiliation:

• Barzilai Medical Center, Department of Oncology, Ashkelon,Israel

Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.

Abstract: Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.

Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.

Method: Systemic compilation of the relevant literature.

Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.

Cite this article as:

Batash Ron , Asna Noam*, Schaffer Pamela, Francis Nicole and Schaffer Moshe , Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review, Current Medicinal Chemistry 2017; 24(27) . https://dx.doi.org/10.2174/0929867324666170516123206